LONGEVERON INC-A

LGVN represents Longeveron Inc., a clinical-stage biotechnology company focused on developing cellular therapies for chronic aging-related and life-threatening conditions. Its pipeline includes investigational treatments for hypoplastic left heart syndrome and Alzheimer's disease, among other areas. The company's work centers on regenerative medicine approaches using specialized cell types. As a clinical-stage firm, its progress depends heavily on trial outcomes and regulatory milestones.

The latest price of LGVN stock changes throughout each trading session. For the most current quote, check the real-time price displayed on this page. That figure reflects the most recent trade and may differ from the previous close or after-hours levels.

LGVN has shown significant price volatility, which is common among small-cap, clinical-stage biotechnology companies. Its share price can react sharply to clinical trial updates, regulatory news, and changes in investor sentiment. Because the company does not yet have a commercial product, headline-driven moves may be pronounced. Reviewing the latest price history and trading volume on this page can help you assess current volatility.

Valuing LGVN is challenging because the company is clinical-stage with no product revenue, so traditional metrics like the P/E ratio are not meaningful. Investors often look at cash position, burn rate, pipeline progress, and potential market opportunities instead. Comparing LGVN's market capitalization and enterprise value to peers can provide context. The latest valuation-related data is available on this page.

LGVN does not pay a dividend. As a clinical-stage biotechnology company, it typically reinvests any available capital into research and development rather than returning cash to shareholders. Therefore, there is no dividend yield or payout schedule to evaluate. For income-focused investors, LGVN would not be a dividend stock.

Key risks include clinical trial failure, regulatory delays, and the need for additional capital, which can dilute existing shareholders. As a small-cap biotech, LGVN may also face limited liquidity and sharp price swings. Competitive pressures and reliance on key personnel are additional factors. These risks can materially affect the company's outlook and stock performance.